Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.
Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H.
Zick A, et al. Among authors: lossos a.
Medicine (Baltimore). 2017 May;96(20):e6931. doi: 10.1097/MD.0000000000006931.
Medicine (Baltimore). 2017.
PMID: 28514312
Free PMC article.